Clinical trials: Attention Deficit
Attention Deficit Hyperactivity Disorder
Open-label, Single-dose Trial to Assess the Pharmacokinetics of Centanafadine Extended-release Capsules in Pediatric Participants With Attention-deficit Hyperactivity Disorder (ADHD)
With the pharmacokinetics (PK) of centanafadine currently being evaluated in adults. The PK of extended-release centanafadine may differ in children compared to adults due to physiological differences in the gastrointestinal…
- Trial name
- NCT04081363
- Testing
- Centanafadine
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Attention Deficit Hyperactivity Disorder (ADHD)
Treatment of Impulsive Aggression in Subjects With ADHD in Conjunction With Standard ADHD Treatment (CHIME 1)
The purpose of this study is to demonstrate the efficacy, safety, and tolerability of SPN-810 in the treatment of Impulsive Aggression (IA) in subjects with Attention-Deficit/Hyperactivity Disorder (ADHD) in conjunction with…
- Trial name
- NCT02618408
- Testing
- SPN-810 (18 mg), SPN-810 (36 mg)
- Where
- 28 sites in United States
- Volunteers
- 333 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
ADHD
Evaluation of SPN-812 (Viloxazine Extended-release Capsule) Low Dose in Children With ADHD
This study will evaluate the efficacy and safety of low doses of SPN-812 in children 6-11 years of age diagnosed with ADHD.
- Trial name
- NCT03247530
- Testing
- 100mg SPN-812, 200mg SPN-812
- Where
- 7 sites in United States
- Volunteers
- 477 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
ADHD
The Efficacy and Safety of PRC-063 in Adult ADHD Patients
The purpose of this randomized, placebo-controlled, double-blind, parallel group study is to evaluate the clinical efficacy and safety of PRC-063 in adults with ADHD
- Trial name
- NCT02139124
- Testing
- PRC-063 25 mg, PRC-063 45 mg, PRC-063 70 mg
- Where
- 38 sites in United States, Canada
- Volunteers
- 375 people
- Sponsor
- Rhodes Pharmaceuticals, L.P.
Attention Deficit Disorder With Hyperactivity
Adult Study / OROS Methylphenidate Hydrochloride (HCL) (OROS MPH) in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
The purpose of this study is to compare the ADHD symptom response of adults with ADHD treated with OROS MPH to those treated with placebo.
- Trial name
- NCT00937040
- Testing
- OROS MPH, OROS MPH Tablets
- Volunteers
- 357 people
- Sponsor
- Ortho-McNeil Janssen Scientific Affairs, LLC
Attention Deficit Hyperactivity Disorder (ADHD)
Crossover Study to Evaluate the Efficacy of AR11 in Pediatric Patients With ADHD in a Laboratory Classroom Setting
This is a dose-optimized, randomized, double-blind, placebo-controlled crossover study in approximately 100 pediatric patients (aged 6 to 12 years) with ADHD.
- Trial name
- NCT01986062
- Testing
- AR11
- Where
- 7 sites in United States
- Volunteers
- 97 people
- Sponsor
- Arbor Pharmaceuticals, Inc.
Attention Deficit Hyperactivity Disorder
Lab School Day Study for CONCERTA of Older Children With ADHD
The purpose of this trial is to determine if the study medication, CONCERTA (methylphenidate HCl), is safe and effective in improving academic performance and behavior in children with attention deficit hyperactivity disorder…
- Trial name
- NCT00799409
- Where
- 2 sites in United States
- Volunteers
- 78 people
- Sponsor
- Ortho-McNeil Janssen Scientific Affairs, LLC
Oppositional Defiant Disorder, Conduct Disorder
Integrated Smart Speaker Promoting Positive Parenting Among Caregivers of Youth With Challenging Behaviors
This project will develop and evaluate the feasibility of an integrated smart speaker and mobile/web-based application, "FamilyNet" (FN) to assist parents in implementing empirically supported behavioral parenting strategies to…
- Trial name
- FamilyNet (NCT05535387)
- Testing
- FamilyNet smart speaker/mobile application
- Where
- United States
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Oregon Research Behavioral Intervention Strategies, Inc.
ADHD, PMS
Prevalence of Lidocaine Ineffectiveness in Adults With and Without ADHD
This work will assess the prevalence in the general population of the ineffectiveness of the anesthetic Lidocaine compared to males with ADHD and females with ADHD with or without PMS.
- Trial name
- NCT03676725
- Testing
- Lidocaine gel
- Where
- 2 sites in United States
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- PhenoSolve, LLC
ADHD
Randomized, Double-blind Safety and Efficacy Study of Lisdexamfetamine Dimesylate (LDX) in Children and Adolescents Aged 6-17
The main aim of this study is to see if giving LDX to children and adolescents aged 6-17 years with ADHD decreases symptoms of ADHD.
- Trial name
- NCT00763971
- Testing
- Lisdexamfetamine Dimesylate (LDX), Methylphenidate Hydrochloride
- Where
- 49 sites in Belgium, France and 8 more
- Volunteers
- 336 people
- Sponsor
- Shire
Attention Deficit Hyperactivity Disorder
Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) With Atomoxetine in Young Adults and Its Effects on Functional Outcomes
This study will evaluate atomoxetine's efficacy in treating attention-deficit/hyperactivity disorder (ADHD) symptoms and atomoxetine's effect on functional outcomes in young adults.
- Trial name
- NCT00510276
- Testing
- Atomoxetine hydrochloride
- Where
- 29 sites in United States, Puerto Rico
- Volunteers
- 445 people
- Sponsor
- Eli Lilly and Company
Attention Deficit Hyperactivity Disorder (ADHD)
Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)
The study is designed to evaluate the efficacy and safety of SHP465 in the treatment of ADHD in children and adolescents (aged 6-17 years).
- Trial name
- NCT02466425
- Testing
- SHP465
- Where
- 36 sites in United States
- Volunteers
- 264 people
- Sponsor
- Shire
Attention Deficit Hyperactivity Disorder
Study to Evaluate Safety & Efficacy of d-Amphetamine Transdermal System vs Placebo in Children & Adolescents With ADHD
This study will evaluate safety and efficacy of d-Amphetamine Transdermal System for the treatment of Attention Deficit Hyperactivity Disorder in children and adolescents.
- Trial name
- NCT01711021
- Testing
- d-Amphetamine Transdermal Patch
- Where
- 3 sites in United States
- Volunteers
- 110 people
- Sponsor
- Noven Pharmaceuticals, Inc.
Attention Deficit Disorder With Hyperactivity
Software Treatment for Actively Reducing Severity of ADHD
The purpose of this study is to evaluate the effects of videogame-like digital therapies on attentional functioning and symptoms in children diagnosed with ADHD.
- Trial name
- STARS-ADHD (NCT02674633)
- Testing
- AKL-T01, AKL-T09
- Where
- 20 sites in United States
- Volunteers
- 348 people
- Sponsor
- Akili Interactive Labs, Inc.
Attention Deficit Disorder With Hyperactivity
A Flexible-Dose Titration Study of Aptensio XR in Children Ages 4 to Under 6 Years Diagnosed With ADHD
This randomized, double-blind, flexible-dose, placebo-controlled, parallel group study is designed to evaluate Aptensio XR® compared to placebo in preschool age children with ADHD.
- Trial name
- EF003 (NCT02683265)
- Testing
- Aptensio XR
- Where
- 2 sites in United States
- Volunteers
- 158 people
- Sponsor
- Rhodes Pharmaceuticals, L.P.
Attention Deficit Hyperactivity Disorder
A Study of TAK-503 in Children and Teenagers With Attention Deficit Hyperactivity Disorder (ADHD)
The main aim of this study is learn more about long-term TAK-503 treatment in children and teenagers with ADHD for whom earlier stimulant treatment did not work. The study has two parts (A and B).
- Trial name
- NCT04085172
- Testing
- Guanfacine hydrochloride (TAK-503), Atomoxetine hydrochloride
- Where
- 50 sites in United States, Austria and 7 more
- Volunteers
- 396 people
- Sponsor
- Shire
Attention-deficit/Hyperactivity Disorder
Maintenance of Efficacy of Extended-Release Guanfacine HCl in Children and Adolescents With Attention-deficit/Hyperactivity Disorder (ADHD)
The primary objective of this study is to evaluate the long-term maintenance of efficacy of Extended-Release Guanfacine HCl in children and adolescents (6-17 years) with attention-deficit/hyperactivity disorder (ADHD) who respond…
- Trial name
- NCT01081145
- Testing
- Extended-release Guanfacine Hydrochloride
- Where
- 81 sites in United States, Belgium and 8 more
- Volunteers
- 528 people
- Sponsor
- Shire
ADHD
SPD503 (Guanfacine Hydrochloride) in ADHD Plus Oppositional Symptoms
To assess efficacy and safety of SPD503(guanfacine hydrochloride) in subjects with ADHD and oppositional symptoms.
- Trial name
- NCT00367835
- Testing
- SPD503 (Guanfacine hydrochloride)
- Where
- 34 sites in United States
- Volunteers
- 217 people
- Sponsor
- Shire
Attention Deficit Hyperactivity Disorder
Predictive Executive Functioning Models Using Interactive Tangible-Graphical Interface Devices in Adults
Current diagnostic aids used in treating ADHD are currently expensive, time intensive, and provide little information about accessory movements in response to a stimulus.
- Trial name
- NCT02127931
- Testing
- Groundskeeper for ADHD group, Groundskeeper for control group
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- CogCubed, Corp
Attention Deficit Hyperactivity Disorder
Adult Attention Deficit Hyperactivity Disorder (ADHD) Study With Amphetamine Sulfate
The purpose of the AR19.004 study is to assess the efficacy of AR19 compared to placebo using the Adult ADHD Investigator Symptom Rating Scale (AISRS)
- Trial name
- NCT03659929
- Testing
- Amphetamine Sulfate
- Where
- 31 sites in United States
- Volunteers
- 320 people
- Sponsor
- Arbor Pharmaceuticals, Inc.